BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 16818949)

  • 21. Preclinical comparison of (111)In-labeled DTPA- or DOTA-bombesin analogs for receptor-targeted scintigraphy and radionuclide therapy.
    Breeman WA; de Jong M; Erion JL; Bugaj JE; Srinivasan A; Bernard BF; Kwekkeboom DJ; Visser TJ; Krenning EP
    J Nucl Med; 2002 Dec; 43(12):1650-6. PubMed ID: 12468515
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of bombesin/gastrin-releasing peptide receptors in human breast cancer and their relationship to steroid receptor expression.
    Halmos G; Wittliff JL; Schally AV
    Cancer Res; 1995 Jan; 55(2):280-7. PubMed ID: 7812958
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro and in vivo application of radiolabeled gastrin-releasing peptide receptor ligands in breast cancer.
    Dalm SU; Martens JW; Sieuwerts AM; van Deurzen CH; Koelewijn SJ; de Blois E; Maina T; Nock BA; Brunel L; Fehrentz JA; Martinez J; de Jong M; Melis M
    J Nucl Med; 2015 May; 56(5):752-7. PubMed ID: 25791989
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Specific binding and growth effects of bombesin-related peptides on mouse colon cancer cells in vitro.
    Narayan S; Guo YS; Townsend CM; Singh P
    Cancer Res; 1990 Nov; 50(21):6772-8. PubMed ID: 2208141
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preclinical pharmacokinetic, biodistribution, imaging and therapeutic efficacy of (177)Lu-Labeled glycated bombesin analogue for gastrin-releasing peptide receptor-positive prostate tumor targeting.
    Lim JC; Cho EH; Kim JJ; Choi SM; Lee SY; Nam SS; Park UJ; Park SH
    Nucl Med Biol; 2015 Mar; 42(3):234-41. PubMed ID: 25498002
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel series of 111In-labeled bombesin analogs as potential radiopharmaceuticals for specific targeting of gastrin-releasing peptide receptors expressed on human prostate cancer cells.
    Hoffman TJ; Gali H; Smith CJ; Sieckman GL; Hayes DL; Owen NK; Volkert WA
    J Nucl Med; 2003 May; 44(5):823-31. PubMed ID: 12732685
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multimodality imaging and preclinical evaluation of 177Lu-AMBA for human prostate tumours in a murine model.
    Liu IH; Chang CH; Ho CL; Chiu SP; Lee WC; Chang TJ; Chen LC; Wu YH; Chuang CH; Fu YK; Lee TW
    Anticancer Res; 2010 Oct; 30(10):4039-48. PubMed ID: 21036718
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies.
    Béhé M; Behr TM
    Biopolymers; 2002; 66(6):399-418. PubMed ID: 12658727
    [TBL] [Abstract][Full Text] [Related]  

  • 29. microPET and autoradiographic imaging of GRP receptor expression with 64Cu-DOTA-[Lys3]bombesin in human prostate adenocarcinoma xenografts.
    Chen X; Park R; Hou Y; Tohme M; Shahinian AH; Bading JR; Conti PS
    J Nucl Med; 2004 Aug; 45(8):1390-7. PubMed ID: 15299066
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 177Lu-labeled RGD-BBN heterodimeric peptide for targeting prostate carcinoma.
    Jiang L; Miao Z; Liu H; Ren G; Bao A; Cutler CS; Shi H; Cheng Z
    Nucl Med Commun; 2013 Sep; 34(9):909-14. PubMed ID: 23708872
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biological evaluation of (177)Lu-labeled DOTA-Ala(SO3H)-Aminooctanoyl-Gln-Trp-Ala-Val-N methyl Gly-His-Statine-Leu-NH2 for gastrin-releasing peptide receptor-positive prostate tumor targeting.
    Lim JC; Cho EH; Kim JJ; Choi SM; Lee Sy; Nam SS; Park UJ; Park SH
    Nucl Med Biol; 2015 Feb; 42(2):131-6. PubMed ID: 25457455
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative study on DOTA-derivatized bombesin analog labeled with 90Y and 177Lu: in vitro and in vivo evaluation.
    Koumarianou E; Mikołajczak R; Pawlak D; Zikos X; Bouziotis P; Garnuszek P; Karczmarczyk U; Maurin M; Archimandritis SC
    Nucl Med Biol; 2009 Aug; 36(6):591-603. PubMed ID: 19647165
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preparation and evaluation of bombesin peptide derivatives as potential tumor imaging agents: effects of structure and composition of amino acid sequence on in vitro and in vivo characteristics.
    Okarvi SM; Jammaz IA
    Nucl Med Biol; 2012 Aug; 39(6):795-804. PubMed ID: 22381782
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Localization of iodine-125-mIP-Des-Met14-bombesin (7-13)NH2 in ovarian carcinoma induced to express the gastrin releasing peptide receptor by adenoviral vector-mediated gene transfer.
    Rogers BE; Rosenfeld ME; Khazaeli MB; Mikheeva G; Stackhouse MA; Liu T; Curiel DT; Buchsbaum DJ
    J Nucl Med; 1997 Aug; 38(8):1221-9. PubMed ID: 9255155
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Radiochemical investigations of (99m)Tc-N(3)S-X-BBN[7-14]NH(2): an in vitro/in vivo structure-activity relationship study where X = 0-, 3-, 5-, 8-, and 11-carbon tethering moieties.
    Smith CJ; Gali H; Sieckman GL; Higginbotham C; Volkert WA; Hoffman TJ
    Bioconjug Chem; 2003; 14(1):93-102. PubMed ID: 12526698
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Spacer site modifications for the improvement of the in vitro and in vivo binding properties of (99m)Tc-N(3)S-X-bombesin[2-14] derivatives.
    Fragogeorgi EA; Zikos C; Gourni E; Bouziotis P; Paravatou-Petsotas M; Loudos G; Mitsokapas N; Xanthopoulos S; Mavri-Vavayanni M; Livaniou E; Varvarigou AD; Archimandritis SC
    Bioconjug Chem; 2009 May; 20(5):856-67. PubMed ID: 19344122
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preclinical evaluation of a new bombesin analog for imaging of gastrin-releasing peptide receptors.
    Shirmardi SP; Gandomkar M; Maragheh MG; Shamsaei M
    Cancer Biother Radiopharm; 2011 Jun; 26(3):309-16. PubMed ID: 21711115
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Selective in vitro targeting of GRP and NMB receptors in human tumours with the new bombesin tracer 177Lu-AMBA.
    Waser B; Eltschinger V; Linder K; Nunn A; Reubi JC
    Eur J Nucl Med Mol Imaging; 2007 Jan; 34(1):95-100. PubMed ID: 16909223
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeted radiotherapy of prostate cancer with a gastrin-releasing peptide receptor antagonist is effective as monotherapy and in combination with rapamycin.
    Dumont RA; Tamma M; Braun F; Borkowski S; Reubi JC; Maecke H; Weber WA; Mansi R
    J Nucl Med; 2013 May; 54(5):762-9. PubMed ID: 23492884
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.